Mast Cell Disorders — Mastocytosis

Mastocytosis encompasses a heterogeneous group of disorders characterized by abnormal proliferation and accumulation of mast cells in one or more organ systems, most commonly bone marrow, skin, and GI tract. The disease results from somatic KIT mutations (most frequently KIT D816V) that confer constitutive kinase activity and autonomous mast cell growth. Mastocytosis can be classified as cutaneous (limited to skin with excellent prognosis) or systemic (SMCD, involving ≥2 extracutaneous organs with more variable outcomes), with systemic forms including indolent, smoldering, aggressive, and leukemic variants. The condition is rare with an estimated prevalence of 1–13 per 100,000 but is clinically significant because mast cell mediator release produces dramatic acute symptoms (anaphylaxis, syncope, flushing) while clonal burden predicts systemic involvement and prognosis. Recognition and appropriate risk stratification are essential for USMLE Step 2 CK, as patients often present with nonspecific symptoms that can be misattributed to other causes.

The pathogenic cornerstone of mastocytosis is a somatic gain-of-function mutation in the KIT gene (encoding the stem cell factor receptor), with KIT D816V occurring in ~80% of adult systemic cases. The D816V point mutation substitutes valine for aspartate at codon 816 in the kinase domain's activation loop, abolishing the requirement for ligand (stem cell factor; SCF) binding for receptor autophosphorylation. This results in ligand-independent, constitutive kinase activity, causing continuous phosphorylation of downstream signaling proteins including phospholipase C-gamma (PLCγ), Ras/MAPK, and PI3K/Akt pathways. The constitutively activated KIT drives mast cell proliferation, survival (via anti-apoptotic signals), and enhanced mediator production, creating an autocrine loop where accumulated mast cells produce their own growth factor (SCF). Other less common KIT mutations (e.g., V560G, exon 8 mutations) and non-KIT mutations (in PDGFRA, FGFR3) cause similar phenotypes, but KIT D816V is the gold standard for molecular diagnosis and predictor of response to imatinib mesylate.

The clinical manifestations of mastocytosis are driven by massive mediator release from abnormally abundant mast cells upon activation (degranulation). Mast cell granules contain preformed mediators (histamine, tryptase, heparin, chymase) released within seconds of activation, and the prolonged degranulation phase produces newly synthesized mediators (prostaglandins, leukotrienes, cytokines including IL-6, TNF-α, IL-1). Histamine is the predominant acute mediator, causing vasodilation (flushing, hypotension, syncope via H1 and H2 receptors), increased vascular permeability (angioedema, urticaria), smooth muscle contraction (bronchospasm, GI cramping), gastric acid hypersecretion, and pruritus. Tryptase, a neutral serine protease released in stoichiometric quantities with histamine, has no direct physiologic effect but serves as a biomarker of mast cell burden and degranulation (elevated baseline tryptase predicts systemic disease; acute rises indicate anaphylaxis). Prostaglandin D2 (produced by mast cells via COX pathway) causes vasodilation, bronchoconstriction, and GI dysmotility; cysteinyl leukotrienes mediate airway reactivity and intestinal inflammation. Heparin released from mast cell granules can cause coagulopathy and osteoporosis with chronic accumulation. Triggers for degranulation include physical stimuli (temperature extremes, mechanical trauma, emotional stress), medications (NSAIDs, opioids, contrast agents), foods, infections, and allergen cross-linking of IgE-bound high-affinity IgE receptors (FcεRI) on the mast cell surface.

In systemic mastocytosis, clonal mast cell proliferation creates a pathologic burden of cells (>10-fold normal) that accumulate in bone marrow (>25% of nucleated cells or focal aggregates in diagnostic criteria), skin (where nests replace normal dermal architecture), GI tract, liver, and spleen. The expanded clone originates from a single hematopoietic progenitor and is monoclonal (confirmed by detecting the same KIT D816V mutation in sorted mast cells), distinguishing it from reactive mast cell hyperplasia. The clonal burden determines disease severity: indolent disease (<25% bone marrow mast cells, normal organ function) has excellent prognosis and minimal life expectancy reduction; smoldering disease has increased burden or mediator elevation but lacks aggressive features; aggressive systemic mastocytosis (ASM) shows >25% marrow involvement with evidence of organ dysfunction (cytopenias, liver fibrosis, hepatosplenomegaly, malabsorption); mast cell leukemia (MCL) shows immature mast cells in blood. Systemic disease also associates with secondary clonal hematologic abnormality (SCHA) in ~25% of cases, including myelodysplastic syndrome or other myeloproliferative neoplasms, which worsens prognosis. The bone marrow microenvironment facilitates mast cell accumulation through enhanced SCF production by fibroblasts and aberrant stromal-mast cell interactions.

Chronic mast cell infiltration of bone marrow and tryptase-mediated activation of osteoclasts causes severe osteoporosis and osteosclerosis (paradoxically both occur in different patients or even simultaneously), with pathologic fractures in ~5–10% of SMCD cases. Heparin released from mast cells inhibits bone formation and activates osteoclasts, while IL-6 and TNF-α promote osteoclastogenesis. Hepatic fibrosis and cirrhosis result from mast cell infiltration of portal tracts and perisinusoidal regions; tryptase and other mediators activate hepatic stellate cells to produce collagen. Splenic involvement can cause massive splenomegaly with cytopenias from hypersplenism.

Over 80% of adult SMCD cases harbor the KIT D816V mutation acquired somatically in hematopoietic cells; this is the defining molecular abnormality and diagnostic criterion. The mutation arises de novo during hematopoiesis in essentially all cases. Patients are not at inherited risk (except rare familial cases with germline KIT mutations, which are extraordinarily uncommon and often present in childhood). The D816V variant confers tyrosine kinase inhibitor (TKI) sensitivity—specifically to imatinib mesylate at high concentrations (though D816V is 10-100 fold less sensitive than wild-type KIT). Detection of KIT D816V in mast cells is sufficient for diagnosis of SMCD without requiring bone marrow morphology in some cases.

KIT exon 8 mutations (V560G, L576P, others) account for ~5% of SMCD, typically show imatinib sensitivity at standard doses (unlike D816V), and may have better prognosis. PDGFRA mutations (particularly F646C) cause a SMCD variant and associate with eosinophilia; these tumors respond to imatinib. FGFR3 mutations and other rare driver mutations cause a minority of cases. Non-mutant KIT SMCD occurs in ~10% of cases, suggesting additional unknown mechanisms.

Childhood-onset cutaneous mastocytosis (urticaria pigmentosa) typically arises from KIT D816V mutations confined to skin mast cells with rare progression to systemic disease; it often regresses spontaneously by adulthood. Adult-onset mastocytosis cutis in older patients rarely progresses. These cutaneous forms have an indolent course and excellent prognosis.

Baseline serum tryptase >20 ng/mL is associated with systemic involvement and predicts more extensive disease burden. Presence of bone marrow mast cell aggregates or >25% involvement defines systemic disease. Secondary clonal hematologic abnormality (SCHA) (concurrent myelodysplasia, chronic myelomonocytic leukemia, or other myeloproliferative disorders) is found in ~25% of SMCD and markedly worsens prognosis; screening bone marrow examination should assess for cytologic atypia. Aggressive features (organ dysfunction, high mediator burden, advanced age) predict rapid progression and shorter survival.

The hallmark of mastocytosis is sudden, unprovoked episodes of intense flushing, pruritus, and constitutional symptoms resulting from mast cell degranulation. Patients describe warm erythema involving face, chest, and trunk—sometimes severe enough to resemble systemic inflammation or fever—often accompanied by profuse diaphoresis. Episodes may occur spontaneously or be triggered by physical stimuli (temperature extremes, hot showers, emotional stress, exercise), foods, medications (NSAIDs, opioids—particularly morphine and codeine, ACE inhibitors, contrast agents), or infections. A single episode typically lasts 15 minutes to 2 hours. Accompanying symptoms include intense pruritus, palpitations, fatigue, and malaise. Many patients become hypervigilant and identify trigger avoidance as the most important coping strategy. The episodes cause significant quality-of-life impairment and psychosocial distress.

Severe hypotensive episodes leading to syncope are a classic presentation of mastocytosis and account for emergency department visits. Acute mast cell degranulation releases large quantities of histamine, causing profound peripheral vasodilation and fluid extravasation into interstitial space, resulting in hypovolemia and cardiovascular collapse. Syncope may occur without warning, during mediator-release episodes, or spontaneously. Prodromal symptoms include dizziness, lightheadedness, palpitations, and severe chest discomfort. Patients often describe recurrent episodes of syncope of unknown etiology before mastocytosis is diagnosed; prior extensive cardiac workup (echocardiography, Holter monitoring) is unrevealing. This classic presentation should prompt consideration of mastocytosis in the differential of "syncope of unknown origin." Syncope is particularly common in indolent SMCD despite lower mast cell burden, suggesting heightened mast cell reactivity in some patients.

Chronic diarrhea, abdominal pain, nausea, and postprandial symptoms are present in 40–80% of SMCD patients. The mechanism involves direct mast cell infiltration of the GI mucosa and lamina propria, combined with local mediator effects (histamine-induced gastric hypersecretion, prostaglandin and leukotriene-mediated smooth muscle contraction and enhanced motility). Peptic ulcer disease occurs in 5–10% and can be severe; histamine-2 receptor antagonists are often needed at high doses. Chronic diarrhea may be secretory (from histamine and prostaglandins) or associated with malabsorption in advanced disease. Food intolerance is common; patients identify triggering foods (high-histamine foods: aged cheeses, fermented foods, shellfish; or direct mast cell degranulation triggers: spicy foods, citrus, alcohol). Hepatomegaly and elevated transaminases indicate liver infiltration; in aggressive disease, cirrhosis develops.

Urticaria pigmentosa is the skin manifestation in ~90% of SMCD and consists of small (2–10 mm), tan-to-brown macules or papules with a characteristic velvety or dimpled appearance distributed on trunk, extremities, and sometimes scalp (notably sparing palms, soles, and mucous membranes). The lesions represent focal accumulations of mast cells in dermis. Applying firm stroking or rubbing to lesions produces the Darier sign—local urticaria and erythema within seconds to 1 minute—a pathognomonic physical finding resulting from mechanical release of mediators. Lesions may be pruritic, especially at night or with temperature changes. Diffuse cutaneous mastocytosis presents as diffuse erythema and infiltration; telangiectasia macularis eruptiva perstans (TMEP) shows fine telangiectasia with minimal pigmentation; mastocytoma is a solitary nodule. Angioedema and acute urticaria may occur superimposed on urticaria pigmentosa during acute episodes.

Acute anaphylaxis (rare but life-threatening) presents with bronchospasm, laryngeal edema, hypotension, tachycardia, and loss of consciousness. This can occur spontaneously or after exposure to triggers (foods, medications, insect stings). Some patients have chronic wheezing and reactive airway disease from baseline mast cell infiltration of airways and enhanced reactivity to triggers. Severe anaphylaxis in mastocytosis differs from IgE-mediated anaphylaxis in that no clear allergen exposure is identified and episodes may recur without obvious trigger—a key clue for diagnosis.

Bone marrow infiltration may cause anemia, thrombocytopenia, and neutropenia in aggressive disease or when secondary clonal hematologic abnormality is present. Hepatosplenomegaly is present in 25–80% of SMCD and ranges from mild to massive; in advanced disease, associated cytopenias from hypersplenism occur.

Smoldering SMCD represents an intermediate category with increased mast cell burden or elevated mediator levels but without organ dysfunction defining aggressive disease. Patients have higher symptom burden, more frequent episodes, and higher tryptase levels than indolent disease but retain normal blood counts and organ function. Risk of progression to aggressive disease is ~5–10% over 5 years.

ASM presents with constitutional symptoms, severe mediator symptoms (frequent flushing, diarrhea, syncope), hepatosplenomegaly, bone pain/fractures, elevated transaminases, and cytopenias. Life expectancy is limited (median ~3–5 years historically, improving with tyrosine kinase inhibitor therapy).

Bone marrow biopsy and aspiration is the gold standard for diagnosis of systemic mastocytosis. The World Health Organization (WHO) criteria require the presence of multifocal, dense infiltrates of mast cells (≥15 mast cells per high-power field or aggregates of ≥15 cells) on biopsy; alternatively, ≥25% of bone marrow nucleated cells are mast cells on aspiration differential. Immunophenotyping reveals **CD117+, trypt

Avoid or use with caution: morphine/codeine, NSAIDs, vancomycin infused rapidly, radiocontrast, and non-selective beta blockers, which blunt the response to rescue epinephrine.